All In Biotech

NDA 020439 · Thea Pharma

Betimol

Timolol · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Oct 21, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Mar 31, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

306

98 Phase 3, 14 recruiting

FAERS reports

12,185

5,726 serious, 584 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 27, 2025.

INDICATIONS AND USAGE Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 31, 1995 Original approval · Type 2 - New Active Ingredient
2 products under this application
  • BETIMOL · TIMOLOL 0.25% · SOLUTION/DROPS, OPHTHALMIC · Discontinued · TE AT
  • BETIMOL · TIMOLOL 0.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure3,052
  • drug ineffective817
  • fatigue493
  • hypersensitivity461
  • off label use418
  • dizziness415
  • diarrhoea409
  • dyspnoea368
  • nausea366
  • eye irritation362
  • fall332
  • headache317

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200515
200617
20079
200861
200994
2010116
2011164
2012164
2013325
2014433
2015568
2016670
2017674
2018850
2019903
20203,868
2021615
2022546
2023551
2024470
2025591
2026474

Recalls

1 FDA enforcement reports for this application.

  • Mar 5, 2024 · Class II · Terminated

    Lack of Assurance of Sterility: Out of specification for volume and compromised container closure.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betimol (Timolol)

2024 spending

$3.6M

Beneficiaries

5,147

14,344 claims

Per beneficiary

$700

$31.58 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$3,132,739
2024$3,600,829

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,308 on PubMed

Sponsor: Thea Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.